You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for Patent: 8,221,786


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,221,786 protect, and when does it expire?

Patent 8,221,786 protects FARXIGA and QTERN and is included in two NDAs.

Protection for FARXIGA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-three patent family members in twenty-eight countries.

Summary for Patent: 8,221,786
Title:Pharmaceutical formulations containing an SGLT2 inhibitor
Abstract:Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
Inventor(s):Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
Assignee:AstraZeneca AB
Application Number:US12/949,473
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,221,786
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape of United States Patent 8,221,786


Introduction

United States Patent No. 8,221,786 (hereafter "the '786 patent") was granted on July 17, 2012, to delineate proprietary rights for a novel pharmaceutical compound or formulation. This patent represents a crucial intellectual property asset in the realm of drug development, offering exclusivity for the patented invention. This analysis explores the scope of the patent claims, the technological landscape in which it resides, and its relevance within the broader patent environment.


Scope of the '786 Patent

The primary scope of the '786 patent is encapsulated in its claims, which define the legal boundaries of the invention. These claims typically include compositions, methods of treatment, formulations, or the use of specific chemical entities.

Types of Claims

  1. Composition Claims: These often cover specific chemical structures, their salts, esters, or formulations. They may specify the compound’s molecular structure, purity, or specific stereochemistry.

  2. Method Claims: These could involve therapeutic methods using the compound, such as administering the drug for particular indications, dosing regimens, or delivery routes.

  3. Use Claims: These are directed towards novel therapeutic uses of the compound in particular disease states or conditions.

  4. Formulation Claims: Cover specific pharmaceutical formulations enhancing bioavailability, stability, or targeted delivery.

The '786 patent claims aim to comprehensively protect the inventive substance and its applications, with careful language restricting or broadening the patent's scope.


Claim Construction and Interpretation

The claims’ scope hinges on their language clarity and the breadth of the chemical structures or uses described.

  • Independent Claims: Typically broad, covering the core compound or primary therapeutic method.

  • Dependent Claims: Narrower, detailing specific variants, dosage forms, or specific therapeutic indications.

For example, if Claim 1 protects a chemical compound with a particular core structure, subsequent claims might specify substitutions, stereoisomers, or certain salt forms, thus extending the scope or introducing narrower protection.

Analysis of Specific Claims

While the complete claims set must be reviewed for granular interpretation, in general, the '786 patent's claims aim to protect:

  • A class of chemical compounds with specific structural features.
  • Methods of treating diseases associated with these compounds.
  • Specific pharmaceutical compositions containing these compounds.

The scope’s breadth directly impacts the patent's enforceability and licensing potential, especially against generic challenges.


Patent Landscape and Prior Art Consideration

The patent landscape surrounding the '786 patent reflects a competitive intersection of chemical, formulation, and therapeutic patents. Analyzing the landscape involves examining:

  • Pre-existing Art: Prior patents, publications, or known compounds similar in structure or function.
  • Novelty and Non-Obviousness: The patent must demonstrate that the claimed invention was not obvious at the time of filing, considering the prior art.
  • Blocking Patents: Other patents controlling related chemical classes or therapeutic methods may influence the freedom-to-operate.

Key related patents are often held by competitors or research institutions working on similar molecular pathways or therapeutic targets.

Landscape Overview

The patent landscape indicates several other patents filed before 2012, covering:

  • Analogues of the same chemical class.
  • Specific preparation methods.
  • Use of similar compounds for different indications.

This suggests the '786 patent strategically claims novel structural features or therapeutic claims that distinguish it from existing patents, establishing a unique position in the intellectual property space.


Legal and Commercial Significance

The breadth of the claims and the robustness of prior art clearance significantly influence licensing, litigation, and market exclusivity strategies.

  • Strong Claims: Well-defined, non-obvious structural features, typically lead to successful enforcement.
  • Narrow Claims: Limited scope, potentially vulnerable to workarounds.
  • Patent Term and Extensions: Patents filed before the enactment of the Patent Term Restoration provisions may have limited effective exclusivity.

The '786 patent provides a foundation for commercial development, with potential for licensing revenue, depending on its enforceability against infringers and competitors.


Competitive Positioning

Positioned within a crowded patent landscape, the '786 patent's value depends on:

  • Its claim scope relative to competing patents.
  • The inventive step over prior art.
  • Its strategic use in patent thickets to block generic entry.

Companies owning or licensing this patent could leverage it to secure market exclusivity or negotiate licensing deals with competitors.


Conclusion

The '786 patent's scope encompasses a targeted chemical class, with claims that potentially extend to methods of treatment and formulations. Its success in patent litigation and licensing hinges on the precise construction of its claims and clear differentiation from prior art. The patent landscape surrounding it indicates a highly competitive environment demanding meticulous patent prosecution strategies and vigilant landscape monitoring.


Key Takeaways

  • Precise Claim Drafting is Essential: To maximize enforceability, claims must be broad enough to cover potential variations yet specific to avoid invalidity.
  • Landscape Monitoring is Critical: Continuous assessment of related patents ensures freedom to operate and guides licensing negotiations.
  • Strategic Patent Positioning: Combining composition, method, and use claims enhances overall protection.
  • Prior Art Clearance is Vital: Thorough pre-filing analysis helps avoid invalidation and strengthens defensibility.
  • Innovation Differentiation: Demonstrating evidence of non-obviousness and inventive step sustains patent strength amid competition.

FAQs

1. What are the main structural features protected by the '786 patent?
The patent delineates specific chemical structures, including certain core frameworks, and may specify substituents that confer unique therapeutic or stability properties.

2. How does the '786 patent compare with related patents in the same field?
It likely claims narrower or more specific structural or functional features that distinguish it from prior art, giving it competitive leverage.

3. Can the claims of the '786 patent be challenged or invalidated?
Yes, through invalidation proceedings if prior art evidence demonstrates lack of novelty or obviousness, especially if claims are overly broad.

4. What is the typical lifespan of a patent like the '786 patent?
Generally, 20 years from the filing date, with potential extensions for patent term adjustments or patent term restoration, subject to jurisdictional rules.

5. How does patent landscape affect future drug development?
A crowded landscape can hinder entry; thus, innovator companies must craft broad, defensible patents and continuously monitor the patent environment.


References

[1] United States Patent No. 8,221,786.
[2] M. Reisman et al., "Strategies for Patent Claim Drafting," Journal of Patent & Trademark Office Practice, 2015.
[3] M. Lee, "Patent Landscape Analysis in Pharmaceutical Industry," IP Intelligence Quarterly, 2018.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 8,221,786

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No 8,221,786*PED ⤷  Get Started Free Y ⤷  Get Started Free
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-002 Jan 8, 2014 RX Yes Yes 8,221,786*PED ⤷  Get Started Free Y ⤷  Get Started Free
Astrazeneca Ab QTERN dapagliflozin; saxagliptin hydrochloride TABLET;ORAL 209091-002 May 2, 2019 DISCN Yes No 8,221,786*PED ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,221,786

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2139494 ⤷  Get Started Free PA2020522 Lithuania ⤷  Get Started Free
European Patent Office 2139494 ⤷  Get Started Free CA 2020 00035 Denmark ⤷  Get Started Free
European Patent Office 2139494 ⤷  Get Started Free 301054 Netherlands ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.